Quantcast
Tag archive for ‘drugs and supplements’
By The Dispatch On Tuesday, December 23rd, 2014
2 Comments

Novo Nordisk’s Saxenda receives FDA approval for chronic weight management treatment

The U.S. Food and Drug Administration today approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The More...

By The Dispatch On Monday, December 22nd, 2014
0 Comments

Melanoma drug, Opdivo, gets FDA approval

The U.S. Food and Drug Administration today granted accelerated approval to Opdivo (nivolumab), a new treatment for patients with unresectable (cannot be removed by surgery) or metastatic (advanced) melanoma who More...

By The Dispatch On Friday, December 19th, 2014
0 Comments

Ovarian cancer drug, Lynparza, receives FDA approval

The U.S. Food and Drug Administration today granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an More...

By Robert Herriman On Tuesday, December 16th, 2014
0 Comments

FDA warns of dangers of powdered pure caffeine

The US Food and Drug Administration (FDA) is advising the public about powdered pure caffeine that is sold on the internet and recommends people avoid these products. In an FDA Blog today, Director of FDA’s More...

By The Dispatch On Sunday, October 26th, 2014
0 Comments

FDA approves Obizur for treating hemophilia A bleeding episodes in adults

The U.S. Food and Drug Administration approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVII] More...

By The Dispatch On Wednesday, August 13th, 2014
0 Comments

Sleep drug, Belsomra, gets FDA nod

The U.S. Food and Drug Administration today approved Belsomra (suvorexant) tablets for use as needed to treat difficulty in falling and staying asleep (insomnia). Belsomra is an orexin receptor antagonist and is More...

By The Dispatch On Friday, August 1st, 2014
2 Comments

Type 2 diabetes drug, Jardiance, receives FDA approval

The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes. Diabetes symptomsPublic domain More...

By The Dispatch On Thursday, July 31st, 2014
1 Comment

Chikungunya and dengue fever anti-viral invented by Florida researcher

The Vaccine & Gene Therapy Institute of Florida (VGTI Florida®), a leading non-profit biomedical research institute, today announced a key milestone achievement in developing novel approaches for the prevention More...

By The Dispatch On Thursday, July 31st, 2014
0 Comments

COPD drug, Striverdi Respimat, receives FDA approval

Today, the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema More...

By The Dispatch On Monday, July 28th, 2014
0 Comments

CLL drug, Imbruvica, receives FDA approval for expanded use

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which More...

By The Dispatch On Thursday, July 24th, 2014
0 Comments

Merck announces start of Phase III study of CMV drug, Letermovir

Merck announced today that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. The multicenter, randomized, placebo-controlled study More...

By The Dispatch On Wednesday, July 23rd, 2014
2 Comments

FDA approves Targiniq ER, extended-release oxycodone, to treat severe pain

Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat More...

By The Dispatch On Wednesday, July 23rd, 2014
1 Comment

Gilead Sciences cancer drug, Zydelig, receives FDA approval

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic More...

By The Dispatch On Thursday, July 17th, 2014
0 Comments

FDA approves Ruconest for the treatment of acute attacks in patients with hereditary angioedema

The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema More...

By The Dispatch On Wednesday, July 16th, 2014
0 Comments

Senators question Gilead Sciences CEO about pricey Hepatitis C drug, Sovaldi

Senate Finance Committee Chairman Ron Wyden, D-Ore., and senior Finance Committee member Chuck Grassley, R-Iowa, Friday requested detailed pricing information on a costly new Hepatitis C virus (HCV) drug. Wyden More...

By The Dispatch On Wednesday, July 16th, 2014
0 Comments

Study questions antibiotic use in hospice patients

CORVALLIS, Ore. – New research suggests that use of antibiotics is still prevalent among terminal patients who have chosen hospice care as an end-of-life option, despite little evidence that the medications improve More...

By The Dispatch On Thursday, July 3rd, 2014
0 Comments

Spectrum Pharmaceuticals Beleodaq for non-Hodgkin lymphoma treatment gets FDA nod

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action More...

By The Dispatch On Friday, June 20th, 2014
0 Comments

Phase I study for MRSA, VISA drug, Debio 1450 launched

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase More...

By The Dispatch On Wednesday, June 18th, 2014
1 Comment

Janssen Announces License Agreement With Vertex for development of VX-787, a novel influenza A drug

PRESS RELEASE TITUSVILLE, NJ, July 18, 2014 – Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, More...

By The Dispatch On Friday, June 6th, 2014
0 Comments

Eloctate, Antihemophilic Factor receives FDA approval for treatment of Hemophilia A

The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment More...


Recent Posts

July 17, 2019, Comments Off on

DISPATCH BLOGS

Grandpa Ernie photo 300x146 Truth in Genesis photo 300x146 Splash Page logo 300x146 Today in History